CEO and co-founder of Celystra Pharma’s Paul Levesque discusses Canadian biotech, rare disease policy, and AI as a healthcare accelerator.

General Manager of UCB Canada’s Rodrigo Reis discusses patient-centric innovation, authentic sustainability, and strengthening digital capabilities.

Associate Vice-President and GM of Incyte’s Chris White discusses Most Favoured Nation pricing impacts, drug access and reimbursement, and wildly authentic leadership.

Founder of Brighthive Innovation Group’s Leandra Wells discusses tech enablement, transforming organization on lean budgets, and prioritizing healthcare in Canada.

CEO of Bloom Burton’s Brian Bloom discusses the themes of the 2025 Bloom Burton conference, return entrepreneurs in the Canadian Life Sciences landscape, and accelerating drug discovery with AI.

Canadian General Manager of argenx’s John Haslam discusses the big impact of rare disease, making key antibodies in the autoimmune space, and pricing strategy reform in Canada.

CEO of Toboggan Labs’ Florencia Herra Vega discusses AI compliance and innovation, applying AI to the whole team instead of individually, and useful technology for quick solutions.

Country Manager of Merz Therapeutics’ Mike Stone discusses commercial launches, the speed of mid-sized pharma, and rebranding DEI.

Leverage’s Ian Howard discusses his time working in the public sector, treating illness versus promoting wellness, and the rise of cosmetic dermatology.

National Director of Account Management of Sales of IQVIA’s Chris Hankey discusses biobanking, digital transformation, and better health outcomes for patients.